Vaginal concentrations of SCY‐078, a novel glucan synthesis inhibitor, following oral administration in mice: 23
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Obstetrics and Gynecology"
DOI: 10.1016/j.ajog.2017.08.044
Abstract: Blood, vulvovaginal tissue and vaginal secretions were collected pre-dose, and at 1, 2, 4, 6, 8, 12, 18 and 24 hours post-dose, following the final dose administered per group. Samples were then processed, extracted via… read more here.
Keywords: scy 078; following oral; concentrations scy; vaginal concentrations ... See more keywords
SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.1204
Abstract: Abstract Background The ability of a pharmacologic agent to reach target organ(s) in therapeutically-meaningful concentrations is one of the fundamental considerations when developing effective, anti-infective treatments. SCY-078 is a novel, oral and intravenous (IV), triterpenoid… read more here.
Keywords: administration; plasma; following oral; penetration ... See more keywords
SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.1207
Abstract: Abstract Background Azoles are the most common anti-fungal agents for the treatment of Aspergillus infections. Echinocandins have demonstrated utility in Aspergillus infections, but are limited in use due to a lack of oral bioavailability. SCY-078… read more here.
Keywords: model invasive; murine model; invasive aspergillosis; scy 078 ... See more keywords
EUCAST in vitro activity of Ibrexafungerp (SCY-078) against C. auris isolates; comparison with activity against C. albicans and C. glabrata and with that of six comparators.
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial agents and chemotherapy"
DOI: 10.1128/aac.02136-19
Abstract: Ibrexafungerp (SCY-078) is a novel first-in-class antifungal agent targeting the glucan synthase. C. auris is an emerging multidrug resistant species that has caused outbreaks on five continents. We investigated the in vitro activity of ibrexafungerp… read more here.
Keywords: scy 078; activity; albicans glabrata; ibrexafungerp scy ... See more keywords
Penetration of Ibrexafungerp (Formerly SCY-078) at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02268-19
Abstract: Ibrexafungerp (IBX), formerly SCY-078, is a novel, oral and intravenous, semisynthetic triterpenoid glucan synthase inhibitor in clinical development for treating multiple fungal infections, including invasive candidiasis. Intra-abdominal candidiasis (IAC) is one of the most common… read more here.
Keywords: scy 078; formerly scy; candidiasis; penetration ... See more keywords
A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02611-18
Abstract: Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and in vitro activity are important efficacy indicators, but accepted susceptibility methods… read more here.
Keywords: scy 078; formerly scy; susceptibility; activity ... See more keywords